Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
IPO Year: 1980
Exchange: NYSE
Website: bio-rad.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $350.00 → $400.00 | Neutral → Buy | Citigroup |
| 8/28/2024 | $340.00 | Equal Weight | Wells Fargo |
| 6/3/2024 | $315.00 | Hold | Jefferies |
| 4/3/2024 | $400.00 → $365.00 | Buy → Neutral | Citigroup |
| 12/7/2023 | $395.00 | Buy | UBS |
| 6/16/2023 | $550.00 | Overweight | Wells Fargo |
| 12/7/2022 | $565.00 | Outperform | RBC Capital Mkts |
| 8/25/2022 | $715.00 | Outperform | Credit Suisse |
| 1/28/2022 | $915.00 → $750.00 | Buy | Citigroup |
| 7/30/2021 | $735.00 → $930.00 | Overweight | Wells Fargo |
The stock market is up solidly this year, thanks to expectations of rate cuts by the Federal Reserve amid easing inflationary pressure, strong corporate earnings and optimism over the potential of artificial intelligence technology’s potential. Building On Gains: The S&P 500 Index, a measure of broader market performance, has gained a robust 14.48% so far this year, and it is up 3.92% for the second quarter. The index last hit a record closing high (5,487.03) on June 18, and breached the 5,500 mark intraday on June 20. Since then, the broader gauge has been going about a consolidation move. The SPDR S&P 500 ETF Trust (NYSE:SPY), an exchange-traded fund that tracks the performance of th
Jefferies assumes Bio-Rad Laboratories (NYSE:BIO) with a Hold rating and lowers Price Target of $315.
-Reuters
Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $412.5, with a high estimate of $480.00 and a low estimate of $365.00. A decline of 2.88% from th
UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $420 to $385.
The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated non-GAAP operating margin of approximately 13.5 to 14.0 percent.
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $2.15 by 6.51 percent. This is a 31.44 percent decrease over earnings of $3.34 per share from the same period last year. The company reported quarterly sales of $610.820 million which missed the analyst consensus estimate of $619.092 million by 1.34 percent. This is a 9.75 percent decrease over sales of $676.844 million the same period last year.
- SEC Filing
Ninety-six percent, or 480 out of the 500 companies comprising the S&P 500 index, are trading at lower market values compared to Wall Street analysts’ price targets, signaling abundant potential profit opportunities for investors. Thus far, April has marked the bleakest month for the U.S. stock market since September 2023, with the S&P 500 index, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), falling by 3.7%. Across all 11 sectors constituting the index, only the Energy Select Sector SPDR Fund (NYSE:XLE) has managed to evade losses. The Real Estate Select Sector SPDR Fund (NYSE:XLRE) emerged as the month’s weakest performer, experiencing a 10% downturn. Higher-than-expected infla
SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)
SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company's global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Suppo
Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences' previous CEO, Jason Gammack, will be leaving the company. Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quant
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader of life science research and clinical diagnostic products, today announced the appointment of Simon May as Executive Vice President and President of the Life Science Group, effective January 4, 2022. He succeeds Annette Tumolo who will retire from this role at that time. Dr. May will be responsible for providing leadership and management of the overall strategy and business direction for the company's Life Science Group global operations. "We are pleased to promote Simon and believe that his strong experience and expertise, coupled with his strengths in building high-performing teams at Bio-Rad, make him ideally suited for this importa
3 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2023. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment. Life Science segment net sales for the third quarter were $260.9 million, a decrease of 1.0 percent compared to the same period in 2023. On a currency-neutr
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-579-2543 within the U.S. or 785-424-1789 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for u
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percent compared to $681.1 million reported for the second quarter of 2023. On a currency-neutral basis, quarterly sales decreased 5.4 percent compared to the same period in 2023. Life Science segment net sales for the second quarter were $250.5 million, a decrease of 16.5 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 15.9 percent compared to the same quart
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-343-4849 within the U.S. or 203-518-9856 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same period in 2023. Life Science segment net sales for the first quarter were $241.7 million, a decrease of 25.3 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 25.2 percent compared to the same quarter
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-274-8461 within the U.S. or (+1) 203-518-9814 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.2 million, a decrease of 6.7 percent compared to $730.3 million reported for the fourth quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.7 percent compared to the same period in 2022. COVID-related sales were approximately $0.3 million in the fourth quarter of 2023 versus approximately $13.4 million in the year ago period. Excluding COVID-related sales, revenue decreased 6.0 percent on a currency-neutral basis.
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 888-259-6580 within the U.S. or +1 416-764-8624 outside the U.S., access code: 36826276. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.9 percent compared to the same period in 2022. COVID-related sales were approximately $0.3 million in the third quarter of 2023 versus approximately $17.2 million in the year ago period. Excluding COVID-related sales, revenue decreased 5.5 percent on a currency-neutral basis. Life Science se
Citigroup upgraded Bio-Rad Labs from Neutral to Buy and set a new price target of $400.00 from $350.00 previously
Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00
Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00
Citigroup downgraded Bio-Rad Labs from Buy to Neutral and set a new price target of $365.00 from $400.00 previously
UBS initiated coverage of Bio-Rad Labs with a rating of Buy and set a new price target of $395.00
Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Overweight and set a new price target of $550.00
RBC Capital Mkts initiated coverage of Bio-Rad Labs with a rating of Outperform and set a new price target of $565.00
Credit Suisse initiated coverage of Bio-Rad Labs with a rating of Outperform and set a new price target of $715.00
Citigroup reiterated coverage of Bio-Rad Labs with a rating of Buy and set a new price target of $750.00 from $915.00 previously
Wells Fargo reiterated coverage of Bio-Rad Laboratories with a rating of Overweight and set a new price target of $930.00 from $735.00 previously
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during Citi's 2024 Global Healthcare Conference in Miami, FL, December 3-5, 2024. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales opera
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 1:15 PM Pacific Time. A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2023. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment. Life Science segment net sales for the third quarter were $260.9 million, a decrease of 1.0 percent compared to the same period in 2023. On a currency-neutr
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-579-2543 within the U.S. or 785-424-1789 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for u
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, at 2:15 PM Eastern Time (11:15 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life scien
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percent compared to $681.1 million reported for the second quarter of 2023. On a currency-neutral basis, quarterly sales decreased 5.4 percent compared to the same period in 2023. Life Science segment net sales for the second quarter were $250.5 million, a decrease of 16.5 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 15.9 percent compared to the same quart
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-343-4849 within the U.S. or 203-518-9856 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
SD - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
DEF 14A - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)